Contracts License Agreements

  • -Feb 2016: Investment of $42.5 million in Pronutria Biosciences, now Axcella Health, a specialist in developing medicines for disease caused by amino acid imbalance. -Sept 2015: Licensing agreement with Lipid Therapeutics for exclusive worldwide rights, except for Europe and Australia, to its experimental medicine for ulcerative colitis.

  • -Feb 2016: Investment of $42.5 million in Pronutria Biosciences, now Axcella Health, a specialist in developing medicines for disease caused by amino acid imbalance. -Sept 2015: Licensing agreement with Lipid Therapeutics for exclusive worldwide rights, except for Europe and Australia, to its experimental medicine for ulcerative colitis.

  • -Feb 2016: Investment of $42.5 million in Pronutria Biosciences, now Axcella Health, a specialist in developing medicines for disease caused by amino acid imbalance. -Sept 2015: Licensing agreement with Lipid Therapeutics for exclusive worldwide rights, except for Europe and Australia, to its experimental medicine for ulcerative colitis.

  • WASHINGTON, Aug 4- As the U.S. Treasury Department decides whether to license sales of Boeing Co and Airbus commercial aircraft to Iran, opponents of last year's nuclear pact with the Islamic republic have launched a lobbying campaign against the deals. The international agreement to curb Iran's nuclear program made such sales possible by easing sanctions on...

  • TORONTO, July 18- Canada's main stock index rose on Monday as banks, some consumer stocks, industrials and materials gained, while energy shares weighed with lower oil prices. The most influential movers on the index included Valeant Pharmaceutical International Inc, which jumped 5.3 percent to C $31.13 after a company it has a licensing agreement with...

  • Pandora CFO: A new paradigm for music consumption

    Michael Herring, CFO at Pandora, discusses the music streaming company's outlook as well as how Pandora stacks up against competitors.